This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Merck, Glenmark file replies in support of dismissing Zetia antitrust suit

( November 16, 2018, 22:31 GMT | Official Statement) -- MLex Summary: Merck and Glenmark filed replies in support of their motions to dismiss the retailer, direct purchaser and end-payor plaintiffs' claims accusing them of entering into an illegal pay-for-delay agreement that kept a generic version of the cholesterol drug Zetia out of the market. They say that retailer plaintiffs cannot argue that their claims are governed by the per se liability standard and end-payors failed to allege “a large and unjustified payment.” Glenmark also argues that direct purchasers’ claims should be dismissed because the relevant settlement agreement never prevented Merck from selling an authorized generic.See documents below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login